Prognostic factors for spinal chordomas and chondrosarcomas treated with postoperative pencil-beam scanning proton therapy: a large, single-institution experience

Fritz R. Murray, MD,¹ James W. Snider, MD,² Ralf A. Schneider, MD,¹ Marc Walser, MD,¹ Alessandra Bolsi, MSc,¹ Alessia Pica, MD,¹ Antony J. Lomax, PhD,^{1,3} and Damien C. Weber, MD^{1,4,5}

¹Center for Proton Therapy, Paul Scherrer Institute, Villigen; ²Department of Physics, ETH, Zurich; ³Radiation Oncology Department, University Hospital of Bern; ⁴Radiation Oncology Department, University Hospital of Zurich, Switzerland; and ⁵Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland

OBJECTIVE The aim of this paper was to evaluate the prognostic factors in surgical and adjuvant care for spinal chordomas and chondrosarcomas after surgery followed by high-dose pencil-beam scanning proton therapy (PBS-PT).

METHODS From 1997 to 2016, 155 patients (61 female patients; median age 55 years) with spinal (cervical, n = 61; thoracic, n = 29; lumbar, n = 13; sacral, n = 46; pelvic, n = 6) classic chordomas (n = 116) and chondrosarcomas (n = 39; most were low grade) were treated with maximal safe resection followed by PBS-PT (median dose prescribed: 74 Gy [relative biological effectiveness], range 48.6–77 Gy). The majority of patients (n = 153, 98.7%) had undergone at least 1 resection prior to PBS-PT (median 1, range 0–5; biopsy only, n = 2). Fewer than half (45.1%) of the surgeries were rated as gross-total resections (GTRs) prior to PBS-PT. Surgical stabilization (SS) was present in 39% of all patients (n = 60). Ninety-one patients (59%) presented with macroscopic tumor at the start of PBS-PT. The median follow-up duration was 64.7 months (range 12.2–204.8 months).

RESULTS The 5-year local tumor control, disease-free survival (DFS), and overall survival were 64.9% (95% CI 56.3%–73.5%), 59.4% (95% CI 50.6%–68.2%), and 77.9% (95% CI 70.6%–85.2%), respectively. In total, 63 patients (40.6%) experienced failure during the follow-up period: local only in 32 (20.6%), distal only in 7 (4.5%), local + distal in 19 (12.3%), surgical pathway failure (SPF) only in 2 (1.3%), local + SPF in 2 (1.3%), and distal + SPF in 1 (< 1%). Univariate analysis identified gross residual disease, the presence of SS, and treatment era prior to 2008 as highly significant for worse outcome, with all 3 remaining significant on multivariate analysis. The type of surgery (GTR or subtotal resection/biopsy) and whether GTR was achieved by en bloc or curettage did not show a significant prognostic effect. Surgical complications prior to PBS-PT were present in 42.5% of all surgically treated patients and were seen more commonly in patients with multiple surgical interventions (p = 0.005) and those operated on with the intent of en bloc resection (p = 0.006).

CONCLUSIONS The extent of resection and metallic stabilization substantially influenced clinical outcomes for patients with spinal chordoma or chondrosarcoma despite high-dose adjuvant PBS-PT. Optimal upfront surgical management of these tumors continues to include GTR, as possible, with prompt adjuvant proton therapy.

<https://thejns.org/doi/abs/10.3171/2019.11.SPINE1927>

KEYWORDS spinal chordoma; spinal chondrosarcoma; pencil-beam scanning; proton therapy; prognostic factors; surgical resection; oncology

ABBREVIATIONS CTCAE = Common Terminology Criteria for Adverse Events; DFS = disease-free survival; GTR = gross-total resection; IMPT = intensity-modulated proton therapy; LC = local control; OS = overall survival; PBS-PT = pencil-beam scanning proton therapy; PSI = Paul Scherrer Institute; PTV = planning treatment volume; PTV1 = PTV subclinical dose; PTV2 = PTV prescription dose; RBE = relative biological effectiveness; SPF = surgical pathway failure; SS = surgical stabilization.

SUBMITTED January 7, 2019. **ACCEPTED** November 15, 2019

INCLUDE WHEN CITING Published online January 31, 2020; DOI: 10.3171/2019.11.SPINE1927.

SPINAL chordomas and chondrosarcomas present particularly challenging scenarios for clinicians in balancing maximization of disease control with minimization of treatment-associated morbidity. As a result of these tumors' juxtapositions, wide en bloc resection is rarely achievable without substantial long-term toxicity. Proximity to critical structures, especially the spinal cord, also challenges the delivery of the high doses of radiotherapy required to affect outcomes in these relatively radioresistant tumor subtypes.

With the advent of particle therapy, and especially pencil-beam scanning proton therapy (PBS-PT), long-term control of this disease and survival have substantially improved.^{4,8,10,12,13,19,20,23} To date, surgical approaches have varied, and multiple series have presented conflicting data regarding the importance of en bloc approaches or gross-total resections (GTRs) for disease outcomes.^{3,6,20,23,25,30} In addition, because of the rarity of these tumors, most efforts have spanned multiple decades, extending across eras that saw multiple improvements in imaging, surgical, and radiotherapeutic practice.

At the Paul Scherrer Institute (PSI), we have delivered exclusively PBS-PT over the last 20 years, with the most frequently treated tumor histologies including chordomas and chondrosarcomas of the base of the skull^{27,28} and spine.²³ We have retrospectively reviewed these patient outcomes and treatment-associated toxicities. Here, we detail our experience with spinal chordomas/chondrosarcomas treated with maximal safe resection and adjuvant proton radiotherapy. A particular focus of this effort was to assess surgical factors associated with resection of spinal chordomas and chondrosarcomas and their prognostic value for outcomes and toxicities associated with treatment of these tumors.

Methods

Patients

Between 1997 and 2016, 155 patients with spinal chordomas ($n = 116$) or chondrosarcomas ($n = 39$) were treated at PSI with PBS-PT. Of note, there were no de-differentiated chordomas, and only a small portion of chondrosarcomas ($n = 3$, 7.7%) were high-grade tumors. All other tumors were described in the initial pathology report as classic chordomas and low-grade chondrosarcomas. No central pathology review, however, was undertaken. A retrospective review was undertaken on an ethics committee–approved protocol. Patients were included if they were at least 18 years old with a minimum follow-up of 12 months. They must also have received PBS-PT for a chordoma or chondrosarcoma centered below the clivus and along the spinal axis. Pathologic review to confirm histology was commonly but not uniformly performed at local institutions.

The median patient age was 55 years (range 23–82 years), with a slight male predominance (94 men and 61 women; Table 1). Spinal level was approximated by the center of tumor growth or postoperative bed. Lesions were more common in the cervical ($n = 61$) and sacral ($n = 46$) regions, rather than the thoracic ($n = 29$) and lumbar ($n = 13$) spine. Although most patients ($n = 109$, 70%) were

treated as part of their initial course of therapy, 30% ($n = 46$) received PBS-PT during treatment for disease recurrence. Due to a systematic enlargement of treatment volumes in 2008 after making an unpublished interim analysis, this series was stratified prior to analysis into patients treated before 2008 ($n = 64$, 41%) and those treated in 2008 and later ($n = 91$, 59%).

A total of 153 patients underwent resection prior to radiotherapy. Two patients underwent biopsy only. Of these, 69 underwent GTR as defined intraoperatively. Twenty-seven (39%) GTRs were performed by an en bloc technique, as defined by the primary surgeon in associated operative notes, whereas 38 (55%) procedures were curettage. Three resections were unable to be characterized with regard to technique, and 1 diagnosis was made by an incidental histological finding during intervention for a benign condition. Of note, the majority of patients ($n = 91$, 59%) had appreciable gross disease on pre-PBS-PT simulation imaging.

Sixty (39%) patients (44 with chordoma and 16 with chondrosarcoma) had surgical stabilization (SS) in place at the time of PBS-PT delivery.

Radiation Therapy

Immobilization and planning techniques have been previously described elsewhere.²³ Patients were most often treated with a 2-phase technique delivering 54 Gy (relative biological effectiveness [RBE]) to a larger volume to address subclinical disease, followed by a boost to a total of 70–74 Gy (RBE) (range 48.6–77.0 Gy [RBE]) to the immediate postoperative bed and any gross residual disease. Treatment generally employed 2–4 posterior beams and usually the first plan was single-field uniform-dose treatment with no organ-at-risk sparing.¹⁴ The treatment plan was changed to intensity-modulated proton therapy (IMPT) after 30–36 Gy (RBE). Standardized institutional dose constraints have been previously described.²⁴

Follow-Up

The majority of patients were followed closely with MRI after treatment at 6 weeks and every 6 months thereafter. At PSI, posttreatment imaging and outside physician records were and continue to be reviewed regularly by the entire clinical team to characterize disease status as well as toxicity. Physician notes, summaries from these conferences, posttreatment imaging, and external records obtained by the research team were retrospectively reviewed for this analysis. Surgical complications were defined as those directly attributable to resection intervention and those arising postoperatively, prior to initiation of radiotherapy. However, based on the inability to clarify which complications were expected by the surgeon prior to each individual intervention, certain “expected toxicities” were likely included as “complications” in the underlying analysis. Adverse events were graded based on the US National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) grading system (v4.0).

Outcomes and Statistical Analysis

Local control (LC), disease-free survival (DFS), and

TABLE 1. Patient and treatment characteristics

Characteristic	All Patients (n = 155)	Chordoma (n = 116)	Chondrosarcoma (n = 39)
Sex, n (%)			
Male	94 (61)	69 (60)	25 (64)
Female	61 (39)	47 (41)	14 (36)
Age in yrs			
Median	55	57	50
Range	23–82	25–82	23–78
Histology & type, n (%)			
Chordoma	116 (75)		
Classic		116 (100)	
De-differentiated		0 (0)	
Chondrosarcoma	39 (25)		
Low grade (grade I–II)			36 (92)
High grade (grade III)			3 (8)
Tumor site/spinal level, n (%)			
Cervical	61 (39)	50 (43)	11 (28)
Thoracic	29 (19)	8 (7)	21 (54)
Lumbar	13 (8)	13 (11)	0 (0)
Sacral	46 (30)	45 (39)	1 (3)
Pelvic	6 (4)	0 (0)	6 (15)
Timing of PBS-PT, n (%)			
Initial diagnosis	109 (70)	84 (72)	25 (64)
Recurrence	46 (30)	32 (28)	14 (36)
Dose in Gy (RBE)			
Median	74	74	70
Range	48.6–77	59.4–77	48.6–75.8
Radiation modality, n (%)			
Proton only	137 (88)	104 (90)	133 (85)
Combined photon-proton	18 (12)	12 (10)	6 (15)
Era, n (%)			
Pre-2008	64 (41)	44 (38)	20 (51)
2008 & later	91 (59)	72 (62)	19 (49)
Resection, n (%)			
Yes	153 (99)	115 (99)	38 (97)
GTR at 1st resection	69 (45)	53 (47)	16 (42)
GTR at last resection	71 (46)	57 (50)	14 (37)
If 1st surgery GTR: technique, n (%)*			
En bloc	27 (39)	23 (43)	4 (25)
Intralesional	38 (55)	29 (55)	9 (56)
Macroscopic tumor prior to PBS-PT, n (%)			
Present	91 (59)	66 (57)	25 (64)
Absent	64 (41)	50 (43)	14 (36)
SS present, n (%)	60 (39)	44 (43)	16 (41)
PTV1 in cm ³			
Median	599	809	386
Range	28–4977	42–4024	28–4977
Median pre-2008	523	645	332
Median 2008 & later	866	897	395

CONTINUED ON PAGE 924 »

» CONTINUED FROM PAGE 923

TABLE 1. Patient and treatment characteristics

Characteristic	All Patients (n = 155)	Chordoma (n = 116)	Chondrosarcoma (n = 39)
PTV2 in cm ³			
Median	368	415	259
Range	11–3749	25–3749	11–3076
Median pre-2008	327	345	212
Median 2008 & later	393	445	268

* Of all patients who underwent GTR, the resection technique for 3 patients is unknown. One patient underwent surgery for a traumatic vertebral fracture with an incidental histopathological malignancy.

overall survival (OS) were assessed as the primary disease-related endpoints. Local failure was declared if imaging or clinical progression or recurrence was noted on the date of first suggestion of recurrence. Disease progression was notated if there was local, regional, or distal recurrence. OS events were defined per date of confirmed death. LC, DFS, and OS were censored at the date of last follow-up if no event had occurred.

Statistical analysis was performed using the IBM SPSS Statistics software package (IBM Corp.).

Results

Patient characteristics and follow-up observations are displayed in Tables 1 and 2, respectively. All 155 patients were followed up for a median of 64.7 months (range 12.2–204.8 months). After stratification by treatment era, the median follow-up for patients treated prior to or during 2007 (n = 64) was 90.6 months (range 17.1–204.8 months), and for patients treated after 2007 (n = 91) it was 57 months (range 12.2–110.7 months). Tumor recurrence or progression was observed in 63 (40.6%) patients (45 [38.8%] with chordoma; 18 [46.2%] with chondrosarcoma): local only in 32 (20.6%), distal only in 7 (4.5%), local + distal in 19 (12.3%), surgical pathway failure (SPF) only in 2 (1.3%), local + SPF in 2 (1.3%), and distal + SPF in 1 (< 1%). A total of 47 patients died (tumor related, n = 32 [68.1%]) during the follow-up period (32 [27.6%] with chordoma; 15 [38.5%] with chondrosarcoma). Of note, at the start of PBS-PT, 91 patients (59%) had macroscopic disease, and 60 (39%) had undergone SS with a metallic implant. The 5-year LC, DFS, and OS for the entire cohort (Tables 3 and 4) were 64.9% (95% CI 56.3%–73.5%), 59.4% (95% CI 50.6%–68.2%), and 77.9% (95% CI 70.6%–85.2%). LC rates at 5 years for chordoma and chondrosarcoma were 67.9% (95% CI 58.1%–77.7%) and 55.9% (95% CI 38.3%–73.5%), respectively.

Univariate analysis did not show a significant difference between the two histological groups with regard to LC (p = 0.49). In accordance with this, 5-year DFS (chordoma: 62.1%, 95% CI 52.1%–72.1%; chondrosarcoma: 51.7%, 95% CI 34.3%–69.1%) and 5-year OS (chordoma: 81.6%, 95% CI 73.6%–89.6%; chondrosarcoma: 67.3%, 95% CI 51.2%–83.4%) were also not substantially different (p = 0.55 and p = 0.36 for DFS and OS, respectively).

As a result, univariate and multivariate analyses (Ta-

bles 5 and 6) for LC, DFS, and OS, based on key surgical and adjuvant therapy prognostic factors, were performed for the entire cohort with these histologies combined. After stratification for treatment era, analysis of the treated volumes showed a significant increase in size of planning treatment volumes (PTVs) for patients treated after 2007 (increase of the median PTV subclinical dose [PTV1] by 40%, p = 0.01). The median PTV prescription dose (PTV2) increased by 18% but was not statistically significantly different from that in the prior era (p = 0.29). Of note, the distribution of tumors throughout the spine before and after 2008 remained relatively balanced (cervical, thoracic, lumbar, sacral, and pelvic, pre-2008: 25, 12, 9, 16, and 2, respectively; 2008 and later: 36, 17, 4, 30, and 4, respectively).

Local Control

On univariate analysis (Table 5), the presence of metallic SS significantly worsened 5-year LC (with SS, 5-year LC = 50.0%; without SS, 5-year LC = 73.4%; p = 0.02). In addition, the treatment era significantly influenced 5-year LC (pre-2008: 5-year LC = 52.1%; 2008 and later: 5-year LC = 77.0%; p < 0.001). Furthermore, the total number of surgeries trended toward significance, with a higher number of surgeries prognosticating for worsened control rates (total number of surgeries ≤ 1, 5-year LC = 71.5%; total number of surgeries ≥ 2, 5-year LC = 56.0%; p = 0.05). A clear relationship was not evident between interval time between surgery and PBS-PT and LC in this setting, with no significant difference found in LC based on time (dichotomous at the median) from the first resection to the start of PBS-PT (< 7.4 months, p = 0.09). On univariate analysis, no statistical significances for 5-year LC rates were found in the case of absent gross residual disease (p = 0.17) or spinal region (p = 0.73). The latter was categorized as either mobile spine (cervical, thoracic, and lumbar) or pelvic and sacral. On multivariate analysis (Table 6), later treatment era (2008 and later, p = 0.001), total number of surgeries (p = 0.03), absence of SS (p = 0.03), and absence of gross residual disease (p = 0.033) were significant prognosticators for improved LC.

Disease Control

In total, 27 distal failures and 5 SPFs (new chordomas or chondrosarcomas arising well outside the current field

TABLE 2. Follow-up observations*

	No. of Events (%)
Survival (entire cohort)	
Alive	108 (69.7)
Dead	47 (30.3)
Death, tumor related	32 (20.6)
Local failure	
Yes	53 (34.2)
No	102 (65.8)
Local failure only	32 (20.6)
Distal failure	
Yes	27 (17.4)
No	128 (82.6)
Distal failure only	7 (4.5)
Distal + local failure	19 (12.3)
SPF	
Yes	5 (3.2)
No	150 (96.7)
SPF only	2 (1.3)
SPF + local failure	2 (1.3)
SPF + distal failure	1 (<1)
Any failure	
Yes	63 (40.6)
No	92 (59.4)
Late toxicity from proton therapy	
Yes	52 (33.5)
CTCAE grade ≥ 3	12 (7.7)
Surgical complication before proton therapy	
Yes	65 (42.5)
No	88 (57.5)
Chordoma	
Local failure	38 (32.8)
Distal failure	20 (17.2)
SPF	3 (2.6)
Any failure	45 (38.8)
Dead at last FU	32 (27.6)
Chondrosarcoma	
Local failure	15 (38.5)
Distal failure	7 (17.9)
SPF	2 (5.1)
Any failure	18 (46.2)
Dead at last FU	15 (38.5)

FU = follow-up.

* Overall median follow-up: 64.7 months (range 12.2–204.8 months). Follow-up was stratified by treatment era. Pre-2008 median follow-up: 90.6 months (range 17.1–204.8 months); 2008 and later median follow-up: 57 months (range 12.2–110.7 months).

in the spine), along with the 53 local failures, were documented as disease failures (Table 2). Consistent with the findings for LC, univariate analysis identified a significant influence of SS ($p = 0.01$) and pre-2008 treatment era ($p = 0.001$) on outcomes, both corresponding with worsened

TABLE 3. Subgroup results: LC, DFS, and OS

Subgroup*	Rate	95% CI
5-yr LC		
Entire cohort	64.9	56.3–73.5%
Chordoma	67.9	58.1–77.7%
Chondrosarcoma	55.9	38.3–73.5%
5-yr DFS		
Entire cohort	59.4	50.6–68.2%
Chordoma	62.1	52.1–72.1%
Chondrosarcoma	51.7	34.3–69.1%
5-yr OS		
Entire cohort	77.9	70.6–85.2%
Chordoma	81.6	73.6–89.6%
Chondrosarcoma	67.3	51.2–83.4%

* Entire cohort = both histologies included.

DFS (Table 5). In addition, the absence of gross residual disease trended toward significance ($p = 0.08$). On multivariate analysis (Table 6), the absence of gross residual disease ($p = 0.02$) and treatment in the later era (2008 and later, $p = 0.001$) significantly increased DFS. In addition, multivariate analysis showed a trend toward a worse outcome with the presence of SS ($p = 0.06$).

Overall Survival

On univariate analysis (Tables 5 and 6), treatment in the later era (pre-2008: 5-year OS = 65.6%; 2008 and later: 5-year OS = 91.1%; $p = 0.001$), absence of gross residual disease (gross residual: 5-year OS = 70.4%; no gross residual: 5-year OS = 89.8%; $p = 0.001$), and absence of SS (SS: 5-year OS = 66.8%; no SS: 5-year OS = 84.8%; $p = 0.002$) significantly correlated with improved OS. In addition, all of these factors proved to be significant prognosticators on multivariate analysis (treatment era, $p = 0.002$; gross residual disease, $p < 0.0001$; SS, $p = 0.01$). In contrast to LC and DFS, on univariate analysis the total number of surgeries ($p = 0.03$) and whether the type of first ($p = 0.02$) and last ($p < 0.001$) resections were GTRs also showed statistical significance for prolonged survival. These factors did not hold significance on multivariate analysis. Furthermore, age older than 55 years at time of PBS-PT showed a trend toward worsened 5-year OS ($p = 0.06$).

Surgical Complications

Surgical complications were encountered in 42.5% of all patients ($n = 65$) who underwent at least 1 resection. Neurological complications were present in 43 patients, including sphincter/bladder dysfunction in 14 and motor deficits in 22. Twelve patients experienced postoperative infections, and 6 patients experienced postoperative hemorrhage. On univariate analysis, an increasing number of surgeries ($p = 0.01$) and en bloc–intention resections ($p = 0.01$) were significantly correlated with increased rates of surgical complication. In addition, surgeries performed for recurrent disease trended toward significant prediction of higher rates of complication ($p = 0.05$). To our knowl-

TABLE 4. Results stratified by era, gross disease, and SS use

	No. of Events (%)	Rate	95% CI
Era			
Pre-2008 (n = 64)			
5-yr LC	37 (57.8)	52.1	39.4–64.8%
5-yr DFS	42 (65.6)	46.3	33.8–58.8%
5-yr OS	36 (60.9)	65.6	54.0–77.2%
2008 & later (n = 91)			
5-yr LC	16 (17.6)	77.0	66.4–87.6%
5-yr DFS	21 (32.8)	71.6	60.2–83.0%
5-yr OS	8 (8.8)	91.1	84.2–98.0%
Gross disease			
Yes (n = 91)			
5-yr LC	34 (37.4)	59.6	48.2–71.0%
5-yr DFS	41 (45.1)	52.6	41.2–64.0%
5-yr OS	33 (36.6)	70.4	60.2–80.6%
No (n = 64)			
5-yr LC	19 (29.7)	72.9	60.2–85.6%
5-yr DFS	22 (34.4)	69.5	56.0–83.0%
5-yr OS	14 (21.8)	89.8	81.4–98.2%
SS use			
Implant (n = 60)			
5-yr LC	26 (43.3)	50.0	34.9–65.1%
5-yr DFS	30 (50.0)	43.9	29.0–58.8%
5-yr OS	29 (48.3)	66.8	53.5–80.1%
No implant (n = 95)			
5-yr LC	27 (28.4)	73.4	63.4–83.4%
5-yr DFS	33 (34.8)	67.9	57.5–78.3%
5-yr OS	18 (18.9)	84.8	76.8–92.8%

edge, no hardware failures were encountered in this series, although the retrospective nature and the outside hospital surgical interventions make this difficult to definitively clarify.

Radiation-Induced Toxicities

Long-term radiation-induced toxicities were encountered in 33.5% of all patients (n = 52). A total of 12 patients (7.7%) presented with high-grade toxicities ($\geq$ grade 3). Ten patients had grade 3 toxicities, including esophageal strictures requiring dilatation (n = 2), insufficiency fractures (n = 3), soft-tissue necrosis (n = 1), subcutaneous fistula (n = 1), neuropathic pain (n = 1), femoral insufficiency requiring hip replacement (n = 1), and ureteral stenosis (n = 1). Another 2 patients presented with grade 4 toxicities: myelitis causing quadriplegia in a patient presenting with quadriplegia from preoperative spinal cord compression that initially improved after therapy and then worsened, and a laryngeal necrosis requiring hyperbaric oxygen therapy. One patient, who received a combined photon-proton treatment for sacral chordoma and was already included in the group of 10 with high-grade toxicities for a subcutaneous fistula, died 48 months after completion of therapy due

to metastatic rhabdomyosarcoma of the bladder, deemed to be potentially radiation induced. Of note, the 19.8-Gy (RBE) proton therapy boost contributed a negligible dose to the bladder in this case.

Discussion

The relative radio-insensitivity of chordomas and chondrosarcomas and their proximity to critical organs at risk when arising around the spinal axis make these tumors particularly challenging for clinicians. Although radical surgery is often not feasible, maximal safe resection followed by appropriate adjuvant therapy remains the standard of care.^{7,9,31} Multiple series have demonstrated that high rates of LC, DFS, and OS are achievable for extracranial chordomas and chondrosarcomas, but that thorough maximal safe resection and high doses of radiotherapy (> 70 Gy [RBE]) are required.^{10,15,18,20} Particle therapy offers conformality and dose that is superior to traditional photon techniques, allowing a dose escalation. The results for LC, DFS, and OS in the current study (the largest reported thus far with exclusively PBS-PT) are consistent with results published by other particle therapy centers.^{11,12,20}

The importance of the surgeon's skill and experience in approaching spinal chordoma and chondrosarcoma cannot be overstated. Several series have documented the importance of achieving maximal resection without unacceptable patient morbidity. These efforts have variably determined that either the extent of resection or surgical approach (en bloc vs curettage) may be prognostic for disease outcomes. For example, Rotondo et al., Bergh et al., Boriani et al., and Talac et al. each determined that en bloc resection techniques reduced rates of recurrence.^{3,6,20,25} Conversely, Snider et al. and York et al. emphasized the importance of rendering the patient free of gross disease prior to the initiation of adjuvant therapy.^{23,30} Schwab et al. noted that, although curettage resections were associated with a higher chance of local failure, the administration of adjuvant radiotherapy seemed to reduce the importance of wide versus "contaminated" margins.²²

In our series, GTR was of prognostic value in predicting outcomes by multivariate analysis. Neither univariate nor multivariate analysis showed statistical significance when comparing en bloc and curettage surgical approaches for disease outcomes of LC, DFS, and OS (p = 0.32, p = 0.47, and p = 0.53, respectively). A particular strength of this analysis is not only its use of modern particle therapy (PBS-PT) but also its use of modern diagnostic imaging (MR) in the radiotherapy simulation and follow-up processes to define disease/recurrence. MRI may have defined residual disease that could have been underappreciated in previous series despite "en bloc" techniques. However, because of this study's retrospective nature and the referral pattern at PSI, the surgical approach was documented by review of surgical notes from various surgeons at numerous institutions from multiple countries. Variability in reporting could clearly have affected results.

In addition, we included a detailed univariate analysis of factors predictive of significant posttreatment morbidity. Resection of spinal tumors is generally associated with high rates of morbidity, ranging from 35% to 46%.^{5,7,16}

TABLE 5. Univariate analysis: LC, DFS, and OS

Characteristic	Value	p Value		
		LC	DFS	OS
Age, yrs		0.485	0.328	0.058
Median	55			
Range	23–82			
Sex		0.921	0.497	0.604
Female	61 (39)			
Male	94 (61)			
Total dose, Gy		0.169	0.398	0.073
<70	23 (15)			
≥70	132 (85)			
Modality		0.718	0.987	0.844
Proton only	137 (88)			
Photon–PBS-PT combined	18 (12)			
Spine region		0.729	0.548	0.576
Cervical, lumbar, & thoracic	103 (66)			
Pelvic sacral	52 (34)			
Treatment setting		0.358	0.542	0.226
Initial	109 (70)			
Recurrence	46 (30)			
Gross residual tumor		0.170	0.076	0.001
Yes	91 (59)			
No	64 (41)			
SS		0.022	0.014	0.002
Yes	60 (39)			
No	95 (61)			
Treatment era		0.001	0.001	0.001
Pre-2008 (focal)	64 (41)			
2008 & later (comprehensive)	91 (59)			
No. of surgeries		0.053	0.122	0.033
0–1	90 (58)			
≥2	65 (42)			
Type of 1st surgery*		0.761	0.382	0.023
GTR	69 (45)			
STR/biopsy	84 (55)			
Technique if 1st surgery GTR†		0.317	0.474	0.527
En bloc	27 (39)			
Curettage	38 (55)			
PTV1 in cm ³		0.812	0.715	0.529
Median	599			
Range	28–4977			
PTV2 in cm ³		0.581	0.514	0.574
Median	368			
Range	11–3749			

STR = subtotal resection.

Values represent the number of patients (%) unless stated otherwise.

* Type of first surgery unknown in 2 patients.

† Of all patients who underwent GTR, the resection technique of 3 patients was unknown. One patient underwent surgery for a traumatic vertebral fracture with an incidental histopathologic finding.

TABLE 6. Multivariate analysis: LC, DFS, and OS

Endpoint & Characteristic*	p Value
LC	
Gross residual disease	0.033
SS	0.028
Era (pre-2008/2008 & later)	0.001
Total no. of surgeries	0.026
DFS	
Gross residual disease	0.018
SS	0.055
Era (pre-2008/2008 & later)	0.001
OS	
Gross residual disease	<0.0001
SS	0.011
Era (pre-2008/2008 & later)	0.002

* Gross residual disease, SS, the pre-2008 era, and a growing total number of surgeries prognosticate for worsened outcomes.

Wei et al. reported postoperative complications as high as 74%.²⁹ The morbidity associated with resection for sacral tumors might be even higher, with published rates of complications up to 100%.^{22,26} In our series, we similarly documented surgical complications in 42.5% of all operated patients, with the majority (66%) being of a neurological nature. Toxicity rates were, not surprisingly, associated with multiple surgical interventions and recurrent disease (Table 5). Increasing clinical target volume size, which corresponds to the extent of resection and resultant surgical bed, was significantly associated with the surgical complication rate.

En bloc approaches were also associated with higher complication rates in this series. Amendola et al. previously published the results of 20 years of experience in a single institution, emphasizing en bloc resection.² The surgical complication rate was 41.7%, with a 1.9% surgical mortality rate. They argued that the high morbidity rate associated with en bloc resections, including resultant functional limitations, can be justified by the long-term survival afforded, especially in the era of high-dose adjuvant particle therapy.^{10,15,18,20} Consistent with this finding, 77.9% of patients included in our series were alive at 5 years. Although surgical complication rates were relatively high, the rate of radiation-induced high-grade (CTCAE events grade ≥ 3) toxicity was less than 8%.

In our series, we observed that more than half of the treatment failures (32/63 [50.8%]; Table 2) were local only. This is in line with the spinal chordoma series from Boston that reported on the outcome of 126 patients treated with surgery and high-dose (median 72.4 Gy [RBE]) proton therapy.²⁰ After a median follow-up of 41 months, the estimated OS and locoregional control was remarkably similar to ours, namely, 81% and 62%, respectively. Noteworthy, these authors observed a significantly higher rate of LC and locoregional control for primary tumors treated with preoperative low-dose radiation therapy. Our institution does not routinely treat spinal chordoma patients with neo-adjuvant radiation, and it remains to be demonstrated

if a preoperative proton therapy is advisable in this setting. More data stemming from ideally prospective studies are needed to answer this critical question.

These findings have informed and support our current clinical approach: patients with spinal chordoma or chondrosarcoma substantially benefit from a planned, multidisciplinary approach in high-volume centers. We emphasize the importance of maximal safe resection (GTR) on first intervention, regardless of technique, and recommend high-dose adjuvant proton therapy promptly at initial presentation rather than observing for recurrence, regardless of the extent of resection. Of note, we observed a limited number of surgical pathway recurrences ($n = 2$, 1.3%) only (Table 2). This is probably consequential to the fact that our institution prophylactically treated the surgical pathway to a dose of 54 Gy (RBE). In particular, early adjuvant radiation in order to prevent salvage treatment, which has been linked to poorer outcomes, has been supported by earlier reviews.^{1,17}

Metallic SS was, again, highly prognostic for worsened LC, DFS, and OS. This finding is consistent with previous reports from our institution.^{21,23} Concern initially focused on the possibility that titanium materials might be contributing to “shadowing” or under-dosage to disease in delivery of adjuvant particle therapy. However, the consistency of this series’ outcomes with previous efforts combining photon and proton techniques to similar total doses (≥ 70 Gy [RBE]) is reassuring that this is likely not the case. In addition, a pattern of failure analysis reported previously does not seem to indicate that local recurrences correlate in position and geometry with surgical SS or expected resultant dose shadowing.²³ SS is generally required in the setting of more extensive initial disease, and may only, therefore, be representative of worse initial disease, which carries a worse prognosis. Nevertheless, the use of alternative implant materials, such as carbon-reinforced polyetheretherketone, may result in improved tumor and target visualization, less CT-artifact delineation times, more accurate proton dosimetry, and more reliable follow-up imaging. This technological enhancement could be helpful in improving outcomes for patients with spinal chordoma and chondrosarcoma going forward.

Treatment era was also highly prognostic in this series. After an internal review of the failures of the early treatment era (prior to 2008), the PSI physician group decided to systematically enlarge treatment volumes. In retrospect, we found a significant enlargement of PTV1 and PTV2 (increase in median volume by 40% and 18%, respectively), which significantly improved long-term results. However, this result could be confounded by other improvements in treatment planning, surgical techniques, and referral patterns across the two eras.

This analysis, despite inherent limitations as a retrospective study, represents one of the largest cohorts of patients with spinal chordoma and chondrosarcoma reported to date. With long-term follow-up of patients treated with adjuvant PBS-PT at a single institution, we believe that this study is particularly informative to the community in improving outcomes for these clinically challenging diseases. This effort is unique in its focus on surgical prognostic factors for both functional and oncological outcomes.

Conclusions

Resection (with the goal of GTR) in experienced hands remains of utmost importance in the management of spinal chordoma and chondrosarcoma. However, en bloc resections might not be superior to curettage techniques, and more aggressive, wide approaches are likely associated with significantly higher rates of surgical complications and functional morbidity. In the era of high-dose adjuvant proton therapy, which has yielded substantially improved treatment outcomes, this is of particular importance, because patients may live for many years with the morbidities associated with not only their disease but also their therapy.

References

1. Ailon T, Torabi R, Fisher CG, Rhines LD, Clarke MJ, Bettgowda C, et al: Management of locally recurrent chordoma of the mobile spine and sacrum: a systematic review. **Spine (Phila Pa 1976)** **41** (Suppl 20):S193–S198, 2016
2. Amendola L, Cappuccio M, De Iure F, Bandiera S, Gasbarrini A, Boriani S: En bloc resections for primary spinal tumors in 20 years of experience: effectiveness and safety. **Spine J** **14**:2608–2617, 2014
3. Bergh P, Gunterberg B, Meis-Kindblom JM, Kindblom LG: Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center-based study of 69 cases. **Cancer** **91**:1201–1212, 2001
4. Björnsson J, Wold LE, Ebersold MJ, Laws ER: Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. **Cancer** **71**:735–740, 1993
5. Boriani S, Bandiera S, Donthineni R, Amendola L, Cappuccio M, De Iure F, et al: Morbidity of en bloc resections in the spine. **Eur Spine J** **19**:231–241, 2010
6. Boriani S, De Iure F, Bandiera S, Campanacci L, Biagini R, Di Fiore M, et al: Chondrosarcoma of the mobile spine: report on 22 cases. **Spine (Phila Pa 1976)** **25**:804–812, 2000
7. Boriani S, Gasbarrini A, Bandiera S, Ghermandi R, Lador R: En bloc resections in the spine: the experience of 220 patients during 25 years. **World Neurosurg** **98**:217–229, 2017
8. Cummings BJ, Hodson DI, Bush RS: Chordoma: the results of megavoltage radiation therapy. **Int J Radiat Oncol Biol Phys** **9**:633–642, 1983
9. DeLaney TF, Kepka L, Goldberg SI, Hornicek FJ, Gebhardt MC, Yoon SS, et al: Radiation therapy for control of soft-tissue sarcomas resected with positive margins. **Int J Radiat Oncol Biol Phys** **67**:1460–1469, 2007
10. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, et al: Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. **J Surg Oncol** **110**:115–122, 2014
11. Holliday EB, Mitra HS, Somerson JS, Rhines LD, Mahajan A, Brown PD, et al: Postoperative proton therapy for chordomas and chondrosarcomas of the spine: adjuvant versus salvage radiation therapy. **Spine (Phila Pa 1976)** **40**:544–549, 2015
12. Indelicato DJ, Rotondo RL, Begosh-Mayne D, Scarborough MT, Gibbs CP, Morris CG, et al: A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. **Int J Radiat Oncol Biol Phys** **95**:297–303, 2016
13. Keisch ME, Garcia DM, Shibuya RB: Retrospective long-term follow-up analysis in 21 patients with chordomas of various sites treated at a single institution. **J Neurosurg** **75**:374–377, 1991
14. Lomax A: Intensity modulation methods for proton radiotherapy. **Phys Med Biol** **44**:185–205, 1999
15. McDonald MW, Linton OR, Moore MG, Ting JY, Cohen-Gadol AA, Shah MV: Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. **Int J Radiat Oncol Biol Phys** **95**:304–311, 2016
16. Molina CA, Ames CP, Chou D, Rhines LD, Hsieh PC, Zadnik PL, et al: Outcomes following attempted en bloc resection of cervical chordomas in the C-1 and C-2 region versus the subaxial region: a multiinstitutional experience. **J Neurosurg Spine** **21**:348–356, 2014
17. Pennicooke B, Laufer I, Sahgal A, Varga PP, Gokaslan ZL, Bilsky MH, et al: Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. **Spine (Phila Pa 1976)** **41** (Suppl 20):S186–S192, 2016
18. Potluri S, Jefferies SJ, Jena R, Harris F, Burton KE, Prevost AT, et al: Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine. **Clin Oncol (R Coll Radiol)** **23**:199–208, 2011
19. Rich TA, Schiller A, Suit HD, Mankin HJ: Clinical and pathologic review of 48 cases of chordoma. **Cancer** **56**:182–187, 1985
20. Rotondo RL, Folkert W, Liebsch NJ, Chen YL, Pedlow FX, Schwab JH, et al: High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. **J Neurosurg Spine** **23**:788–797, 2015
21. Rutz HP, Weber DC, Sugahara S, Timmermann B, Lomax AJ, Bolsi A, et al: Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. **Int J Radiat Oncol Biol Phys** **67**:512–520, 2007
22. Schwab JH, Healey JH, Rose P, Casas-Ganem J, Boland PJ: The surgical management of sacral chordomas. **Spine (Phila Pa 1976)** **34**:2700–2704, 2009
23. Snider JW, Schneider RA, Poelma-Tap D, Stieb S, Murray FR, Placidi L, et al: Long-term outcomes and prognostic factors after pencil-beam scanning proton radiation therapy for spinal chordomas: a large, single-institution cohort. **Int J Radiat Oncol Biol Phys** **101**:226–233, 2018
24. Stieb S, Snider JW III, Placidi L, Kliebsch U, Lomax AJ, Schneider RA, et al: Long-term clinical safety of high-dose proton radiation therapy delivered with pencil beam scanning technique for extracranial chordomas and chondrosarcomas in adult patients: clinical evidence of spinal cord tolerance. **Int J Radiat Oncol Biol Phys** **100**:218–225, 2018
25. Talac R, Yaszemski MJ, Currier BL, Fuchs B, Dekutoski MB, Kim CW, et al: Relationship between surgical margins and local recurrence in sarcomas of the spine. **Clin Orthop Relat Res** (397):127–132, 2002
26. Verlaan JJ, Kuperus JS, Slooff WB, Hennipman A, Oner FC: Complications, secondary interventions and long term morbidity after en bloc sacrectomy. **Eur Spine J** **24**:2209–2219, 2015
27. Weber DC, Malyapa R, Albertini F, Bolsi A, Kliebsch U, Walser M, et al: Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. **Radiation Oncol** **120**:169–174, 2016
28. Weber DC, Murray F, Combescure C, Calugaru V, Alapetite C, Albertini F, et al: Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. **Radiation Oncol** **129**:520–526, 2018
29. Wei F, Liu Z, Liu X, Jiang L, Dang G, Passias PG, et al: An approach to primary tumors of the upper cervical spine with spondylectomy using a combined approach: our experience with 19 cases. **Spine (Phila Pa 1976)** **43**:81–88, 2018
30. York JE, Berk RH, Fuller GN, Rao JS, Abi-Said D, Wildrick

- DM, et al: Chondrosarcoma of the spine: 1954 to 1997. **J Neurosurg** **90** (1 Suppl):73–78, 1999
31. Zagars GK, Ballo MT: Significance of dose in postoperative radiotherapy for soft tissue sarcoma. **Int J Radiat Oncol Biol Phys** **56**:473–481, 2003
-

Disclosures

Dr. Snider: consultant for Siemens Healthineers, Pyrexar, and Varian Medical Systems; and patent holder with ProtonGRID.

Author Contributions

Conception and design: Weber. Acquisition of data: Murray,

Snider. Analysis and interpretation of data: Weber, Murray. Drafting the article: Murray. Critically revising the article: Weber, Snider, Schneider, Walser, Bolsi, Pica, Lomax. Reviewed submitted version of manuscript: Weber, Snider, Schneider, Walser, Bolsi, Pica, Lomax. Approved the final version of the manuscript on behalf of all authors: Weber. Statistical analysis: Murray, Snider. Study supervision: Weber.

Correspondence

Damien C. Weber: Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen, Switzerland. damien.weber@psi.ch; damiencharles.weber@uzh.ch.